share_log

HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Lowers Price Target to $18

Benzinga ·  Jul 17 06:22

HC Wainwright & Co. analyst Robert Burns maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and lowers the price target from $20 to $18.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment